Investigation of Pharmacokinetics, Safety and Tolerability of Oral NNC0385-0434 in Participants With Various Degrees of Impaired Renal Function and in Participants With Normal Renal Function
Latest Information Update: 28 Dec 2023
At a glance
- Drugs NNC0385 0434 (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 16 Sep 2022 Status changed from recruiting to discontinued.
- 24 Aug 2022 Planned End Date changed from 14 Sep 2022 to 14 Dec 2022.
- 24 Aug 2022 Planned primary completion date changed from 22 Jul 2022 to 14 Dec 2022.